Kornimate/medical-research-clean huggingface dataset:
lung diffusing capacity for nitric oxide as a marker of fibrotic changes in idiopathic interstitial pneumonias

Conditions: Usual Interstitial Pneumonia; Nonspecific Interstitial Pneumonia

Summary: the diagnosis of idiopathic interstitial pneumonia (iip) is based on computed tomography (ct) imaging, whereas lung function studies are used for staging and follow up. lung diffusing capacity for carbon monoxide (dlco) is generally reduced but weakly correlated with the severity of ct-determined fibrotic process. a possible explanation of this finding is that dlco is relatively insensitive to changes in alveolar membrane diffusive conductance (dmco). lung diffusion capacity for nitric oxide (dlno) was strongly correlated with ct-determined amount of fibrosis/honeycombing in both usual and non-specific interstitial pneumonias. moreover. both dlno and dmco were below the lower limit of normality even in patients with small amount of fibrosis. measurement of dlno may provide a more reliable assessment of fibrotic changes than dlco because it better reflects dmco.

rationale: lung diffusing capacity for carbon monoxide (dlco) is decreased in both usual interstitial pneumonia-idiopathic pulmonary fibrosis (uip-ipf) and nonspecific interstitial pneumonia (nsip), but is weakly related to computed tomography (ct)-determined fibrotic changes. objectives: to determine whether measurement of lung diffusing capacity for nitric oxide (dlno) better reflects fibrotic changes than dlco. methods: dlno and dlco were measured simultaneously in 30 patients with uip-ipf and 30 with nsip. the amount of pulmonary fibrosis was estimated by volumetric analysis of visually bounded areas showing reticular opacities and honeycombing. alveolar membrane conductance (dmco) and pulmonary capillary volume (vc) were calculated.

Eligibility criteria:
inclusion criteria: * chest computed tomography (ct) scan diagnosis of either usual interstitial pneumonia-idiopathic pulmonary fibrosis (uip-ipf) or idiopathic nonspecific interstitial pneumonia (nsip) exclusion criteria: * symptoms/signs or specific serum markers of an underlying autoimmune process * previous environmental/occupational exposure to fibrogenic dusts * use of fibrogenic medications

Keywords: lung diffusing capacity idiopathic interstitial pneumonias
study to investigate the immune response and safety of prophylactic vaccines in patients treated for multiple sclerosis

Conditions: Multiple Sclerosis, Relapsing-Remitting

Summary: the aim of this study is to determine whether prophylactic vaccines recommended are effective and safe in patients with multiple sclerosis(ms) under ms-specific therapy.

protective vaccines against communicable diseases are of major importance in patients with autoimmune diseases or impaired immune response. in patients with multiple sclerosis bacterial or viral infections may lead to disease progression and vaccines can protect from these infections and prevent disease progression. fear of possible side effects of vaccines have led to a general restraint regarding vaccination of patients with ms. however, previous studies have not shown an increased risk of disease progression following hepatitis b vaccination and even a reduced progression rate in relapsing-remitting ms after tetanus/diphtheria vaccination. various disease modifying treatments (dmt) are available for ms, most of these therapies lead to an impairment of the immune system affecting the immune response to vaccination. additionally, live attenuated vaccines may lead to severe side-effects if used in patients under dmt treatment. testing immune response after vaccination may be prudent in subjects undergoing dmt to assure vaccination success since only a limited number of studies have investigated immune response after vaccination in patients with ms undergoing dmt.

Eligibility criteria:
inclusion criteria: * established diagnosis of multiple sclerosis * age: 18 - 70 years * indication for vaccination (according to public recommendation) * written informed consent exclusion criteria: * current relapse of ms * unstable disease * contraindication for vaccination (acute infection, fever, allergy to vaccine) * unable to comply with study procedures

Keywords: vaccine antibody response relaps rate expanded disability status scale
evaluation of the effects of lunii on pre-operative anxiety and on the post-operative period in children with cleft lip and palate admitted for alveolar bone graft: pilot study

Conditions: Cleft Lip and Palate

Summary: the literature on the effects of various devices on per-operative anxiety is scarce. there is currently no study on the effects of an interactive storyteller on per-operative anxiety in pediatric surgery. the interactive story teller lunii (available over the counter in france) would reduce pre-operative anxiety, with post-operative effects on pain and hospitalization time.

the literature on the effects of various devices on per-operative anxiety is scarce. there is currently no study on the effects of an interactive storyteller on per-operative anxiety in pediatric surgery. the interactive story teller lunii (available over the counter in france) would reduce pre-operative anxiety, with post-operative effects on pain and hospitalization time. patients admitted for an alveolar bone graft with an iliac donor site as part of the treatment of their cleft lip and palate will be include for two reasons: 1. it is a homogeneous population - same condition, same treatment, same age at surgery, standardized procedure; 2. it is a population with long individual medical histories and, potentially, subjected to significant surgery-related stress. patients will be randomized into two groups: with lunii and without lunii. in the lunii group, the interactive story teller lunii will be delivered the day before surgery during the pre-operative medical visit.

Eligibility criteria:
inclusion criteria: * children aged 4 to 6 years. * alveolar bone graft with iliac crest donor site in children with unilateral or bilateral cleft lip and palate * primary alveolar bone graft or first side when bilateral cleft * followed at necker since birth and operated according to the protocol used in the department. * consent signed by the holder (or holders) of parental authority exclusion criteria: * medical care different from the usual protocol applied in the service (secondary surgery, age \> 7 years) * known psychomotor delay, associated rare syndrome or disease, known psychiatric disorders, other surgical procedures between hard palate closure and alveolar bone graft * possession and/or prior use of lunii by the child

Keywords: per-operative stress per-operative anxiety pediatric surgery
adding paracetamol to ibuprofen for treatment of patent ductus arteriosus in preterm infants

Conditions: Ductus Arteriosus, Patent

Summary: the purpose of this study is to determine if adding paracetamol to ibuprofen is superior to ibuprofen only for treatment of patent ductus arteriosus (pda) in preterm infants.

randomized control trial to determine if adding paracetamol to ibuprofen is superior to ibuprofen only for treatment of patent ductus arteriosus (pda) in preterm infants.

Eligibility criteria:
inclusion criteria: * preterm infants born at 24-37 gestational age * diagnosis of hemodynamically significant patent ductus arteriosus * medical staff decided to treat with ibuprofen * parents have signed informed consent exclusion criteria: * contraindication for ibuprofen * alanine transaminase /aspartate transaminase≥ 200 u/l * significant congenital heart disease

Keywords: patent ductus arteriosus pda preterm infant electrocardiography paracetamol acamol ibuprofen placebo
veterans coping long-term with active suicide

Conditions: Suicide

Summary: the proposed study seeks to test the efficacy of an intervention to reduce suicide behaviors in veterans. the veterans coping long term with active suicide program (clasp-va) is an innovative, telephone-based intervention that combines elements of individual therapy, case management, and significant other/family therapy and is designed to be integrated into a va system.

suicide is a leading cause of death for military personnel, and for the first time in recorded history, rates of military suicides are exceeding civilian rates. despite public and patient health costs associated with suicidal ideation and behavior, existing efforts haven't appreciably reduced rates of suicidal behavior in the military. consequently, finding novel, efficacious, and acceptable methods to reduce suicide behaviors is imperative. the veteran's coping long term with active suicide program (clasp-va) is a unique suicide reduction intervention that directly targets high-risk patients at the time of hospital discharge. it is one of the few empirically-developed and promising interventions (e.g., strong pilot data) for individuals hospitalized for suicide behavior. the primary objective of this study is to test the efficacy of the clasp intervention compared to a treatment as usual plus safety assessment and follow-up evaluation (safe) control condition. efficacy will be determined by primary outcomes including: number of attempts, number of re-hospitalizations, severity, and chronicity of suicidal ideation. a secondary objective is identifying the types of patients who receive the most benefit from the clasp-va intervention.

Eligibility criteria:
inclusion criteria: * suicide attempt or suicidal ideation with any methods, plan, and/or intent to make a suicide attempt within 1 week of hospitalization * age greater than 18 * have a telephone * ability to speak, read, and understand spoken english sufficiently well to complete the procedures of the study exclusion criteria: * long-term psychiatric disorder * diagnosis of borderline personality disorder * cognitive impairment which would interfere with adequate participation in the project (mmse \<20)

Keywords: depression prevention veterans health
ctla-4 /pd-l1 blockade following transarterial chemoembolization (deb-tace) in patients with intermediate stage of hcc (hepatocellular carcinoma) using durvalumab and tremelimumab

Conditions: Intermediate Stage of Hepatocellular Carcinoma; Hepatocellular Carcinoma

Summary: the purpose of this study is to determine the safety and efficacy of immunotherapy durvalumab and tremelimumab combined with deb-tace in patients with hepatocellular carcinoma.


Eligibility criteria:
inclusion criteria: * signed informed consent form * age ≥18 years. * newly diagnosed with hepatocellular carcinoma * have measurable disease * have disease that responds to deb-tace * eastern cooperative oncology group (ecog) performance status 0 or 1 * body weight \>30 kg * evidence of clinical or radiographic ascites with a score \< 7 * patients must have adequate organ function defined by study-specified laboratory tests. * evidence of post-menopausal status or negative pregnancy test * willing and able to comply with study procedures * willing to undergo a liver biopsy exclusion criteria: * anyone involved with the planning and/or conduct of the study. * has participated in another investigational study during the last 6 months. * any concurrent anticancer therapy or received therapy ≤30 days prior to study. * major surgical procedure at the time of study enrollment or within 28 days prior to the first dose of ip. * have a diffuse hcc (hepatocellular carcinoma), vascular invasion or extrahepatic tumor. * main portal vein thrombosis present on imaging. * history of hepatic encephalopathy within past 12 months or require medications to prevent or control encephalopathy. * ascites within 6 weeks prior to study treatment. * any contraindications for embolization. * has an active infection such as tb, hiv, hepatitis b or c. * history of another primary malignancy. * history of leptomeningeal carcinomatosis. * history of active primary immunodeficiency. * any unresolved toxicities from previous anticancer therapy. * grade ≥2 neuropathy. * history of bleeding disorder. * history or current use of immunosuppressive medications within 14 days prior to study medications. * has an active known or suspected autoimmune disease. * patients with hypothyroidism. * any active skin conditions. * history of allogenic organ transplantation. * significant heart disease. * patients weighing \< 30 kg. * patients with celiac disease not controlled by diet alone. * patient with uncontrolled intercurrent illness including, but not limited to, uncontrolled infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. * have received a live vaccine within 30 days prior to study drug. * woman who are pregnant or breastfeeding. * known allergy or hypersensitivity to the study drug. * have received durvalumab, tremelimumab, anti-pd-1, anti-pd-l1 or anti-ctla-4 in a prior study. * unwilling or unable to follow the study schedule for any reason.

Keywords: hcc durvalumab tremelimumab immunotherapy pd-l1 antibodies hepatocellular carcinoma ctla-4 deb-tace
early support and physiotherapy for children and their motor skills

Conditions: Infant; Cerebral Palsy; Neonatal

Summary: the app-emot-quali project proposed here is the first phase in the implementation of a care pathway supported by a digital tool. it consists of a qualitative study allowing individual interviews to be conducted with parents of infants at high risk of cerebral palsy and health professionals in order to identify and precisely describe the needs and difficulties present during the child's rehabilitative care during the first months of life.


Eligibility criteria:
inclusion criteria: 1. for the parents: parents of children under 24 months of age at high risk of cerebral palsy who have given their oral consent. children at high risk of cerebral palsy are defined as : * premature children ≤ 31 wg + 6 days or birth weight less than 1000g. * children who have had a stroke or stage 2 or 3 hypoxia-ischemia according to the sarnat classification. the selection of parents may be retrospective with less than 24 months since hospital discharge. 2. for the health professionals: physiotherapists, psychomotricians, psychologists and doctors involved in the care of children at high risk of cerebral palsy. exclusion criteria: * a person who is physically or cognitively unable to participate in a one-on-one interview or who does not have a sufficient command of the french language. * parents aged \<18 years * parents in protective custody * parents of children with major orthopedic or traumatic disorders unrelated to the high risk of cerebral palsy. * parents of a child with a genetic disease.
oral sildenafil and intravenous milrinone on postoperative pulmonary hypertension

Conditions: Pulmonary Hypertension

Summary: pulmonary hypertension (ph) is a consequence of an increase in pulmonary vascular resistance (pvr), pulmonary blood flow, pulmonary venous pressure, or a combination of these elements. pulmonary arterial hypertension is a frequent complication of congenital heart disease, particularly in patients with systemic-to-pulmonary shunts. persistent exposure o f the pulmonary vasculature to increased blood flow and pressure may result in vascular remodeling and dysfunction. this leads to increased pulmonary vascular resistance and, ultimately, to reversal of the shunt and development of eisenmenger's syndrome. it may be more appropriate to define pulmonary hypertension according to the ratio of mpap to mean systemic arterial pressure (mpap/map) because children may have a low mean systemic blood pressure. mpap/map ratio of \ 0.5 is indicative of severe pulmonary hypertension

30 patients were randomly allocated in two equal groups; group ms (received intravenous milrinone and oral sildenafil) and group m (received only intravenous milrinone). demographic data, patient's clinical data and different intraoperative times were recorded. in 1st postoperative 24 hours, we recorded; hemodynamic parameters \[mean pulmonary arterial pressure (mpap), mean systemic arterial pressure (map), heart rate, central venous pressure\]. we calculated mpap/map and inotropic score. the incidence of pulmonary hypertensive crisis, side effects of studied drugs and complications related to pulmonary artery catheter were recorded.

Eligibility criteria:
inclusion criteria: - thirty patients in the age range 2-24 months scheduled for surgical closure of ventricular septal defect (vsd) associated with postoperative pulmonary hypertension \[diagnosed in all patients by preoperative echocardiography and confirmed invasively by the pulmonary catheter before transfer to icu by mean pulmonary arterial pressure (mpap) \> 25 mmhg or mean pulmonary arterial pressure (mpap) /mean systemic arterial pressure (map) \> 0.33\] were enrolled in this study. exclusion criteria: * patients with pre-existing obstructive lung disease, mitral valve disease, left ventricular dysfunction, and patients receiving preoperative pulmonary vasodilators

Keywords: pediatric cardiac sildenfil milrinone pulmonary hypertension
effect of intravitreal vegf-trap eye on polypoidal choroidal vasculopathy

Conditions: Exudative Age-related Macular Degeneration; Polypoidal Choroidal Vasculopathy

Summary: effects of vegf trap-eye (aflibercept) in treatment-naive polypoidal choroidal vasculopathy (pcv) will be evaluated.

efficacy of vegf trap-eye (aflibercept, eylea) for exudative age-related macular degeneration (amd) was demonstrated in the phase iii view study. polypoidal choroidal vasculopathy (pcv) is considered as a subtype of exudative amd, however it is reportedly different from choroidal new vessels based on the histologic studies. the aim of this study is to evaluate effects of vegf trap-eye in treatment of pcv, which was diagnosed using indocyanine green (icg) angiography. vegf trap-eye will be injected intravitreally bimonthly after 3 monthly loading dose for 12 months in treatment-naive pcv patients. the efficacy will be evaluated on preserving visual acuity and improving angiographic features at 12 months.

Eligibility criteria:
inclusion criteria: * submacular pcv diagnosed using icg angiography with no previous treatment (branching vascular network with or without polypoidal dilation in icg angiography) * presence of signs of recent activity of pcv 1. visual acuity between 20/40 and 20/320 2. active leakage in fluorescein angiography 3. presence of any fluid in oct(optical coherence tomography)-intraretinal, subretinal, sub-retinal pigment epithelial exclusion criteria: 1. extramacular pcv 2. subretinal hemorrhage or other retinal lesions blocking angiographic characteristics in more than 50% area of pcv lesion. 3. previous treatment of intravitreal injections (anti-vegf, steroid or other agents) 4. previous treatment of photodynamic therapy 5. previous ocular surgery except cataract surgery before 3 or more months 6. presence of exudative amd in the other eyes requiring anti-vegf treatment (intravitreal bevacizumab was reported to affect the other eye.) 7. presence of other ocular diseases which may affect visual acuity (glaucoma, cataract with opacity involving visual axis, etc) 8. presence of uncontrolled systemic disease (diabetes mellitus, hypertension, ischemic heart disease, cerebral infarction, etc) 9. patients who cannot understand or conform to the study protocol. 10. patients who refuse to agree to the informed consent. 11. patients with contraindication to aflibercept * ocular or periocular infection * active severe intraocular inflammation * known hypersensitivity to aflibercept or to any of the excipients
whole body vibration in children with cerebral palsy

Conditions: Cerebral Palsy; Spastic

Summary: some positive effects of whole body vibration applications in reducing spasticity, improving walking ability, and increasing walking speed have been reported in children with cp, but the evidence is not strong enough. therefore, this study was planned to evaluate the effect of whole body vibration treatment on spasticity, gait, balance, and motor performance in children with spastic cp. this study hypothesis that whole body vibration provides an additive improvement on spasticity, balance, gait and motor performance.

participants will be evaluate at baseline, after the conventional physiotherapy program, and after whole body vibration training program. during this period, the participants who were recruited whole body vibration training program, whole body vibration will be applied in addition to conventional physiotherapy sessions comprised 45 min, 2 days a week, during 8 week.

Eligibility criteria:
inclusion criteria: * children diagnosed with spastic diplegic cp in gmfcs levels i and ii, cfcs level i and macs levels i and ii * aged 6-17 years * ability to cooperate with the evaluations * walking independently with or without an orthosis (without any support) exclusion criteria: * having a recent injury affecting the lower extremities * having undergone any surgery or botulinuim toxin application within the last six months * having severe cardiopulmonary or systemic problems * having uncontrolled seizures, visual or hearing problems preventing the evaluations

Keywords: cerebral palsy whole body vibration gait balance
efficacy of helicobacter pylori eradication, anti-d and danazol combination in steroid dependant or refractory immune thrombocytopenia (itp)

Conditions: Thrombocytopenia

Summary: proportion who would avoid splenectomy at 6 months of follow up

1. if urea breath test (+); omeprazole 20mg bid, amoxicillin 1000mg bid and clarithromycin 500mg bid for 1 week. second line helicobacter pylori eradication will be permitted after failure of first line treatment. 2. anti-d anti-ro 50 μg/kg iv for 2 days (d1, 2) 3. danazol maintenance (from d1): danazol will be continued at least 3 months. the dose of danazol can be reduced according to the adverse effects, especially in premenopausal women.

Eligibility criteria:
inclusion criteria: * 1.itp is defined by * (a) a true thrombocytopenia on blood smear, (b) adequate megakaryopoiesis on bone marrow examination, (c) the absence of clinically apparent associated conditions or cause of thrombocytopenia * 2.steroid dependant itp: more than 10 mg of prednisolone per day is required to maintain a platelet count above 20x109/l (minimum follow up duration: 3 months after diagnosis) * 3.steroid refractory itp: a platelet count less than 20x109/l despite of treatment with full dose of steroid (prednisolone 1mg/kg for at least 4 weeks) * 4.18 years old or more exclusion criteria: * 1.patients who have a cause of thrombocytopenia such as hiv infection, lymphoproliferative disease, liver disease, definite sle or drug * 2.pregnancy * 3.splectomized patients * 4.rh- blood type * 5.hemoglobin \< 10g/dl * 6.known hypersensitivity to immunoglobulins * 7.a positive direct antiglobulin test * 8.clinically relevant hepatic or renal disease

Keywords: itp
orbital fractures measurement: intraoperative versus computed tomography (ct) scan

Conditions: Orbital Fractures

Summary: purpose to compare the orbital fracture size measured by orbital ct scan and compare it to the actual orbital fracture size intraoperatively in patients who needed surgical intervention to correct the fracture. hypothesis: there is difference between the ct measure fracture size and the actual intraoperative size.


Eligibility criteria:
inclusion criteria: * with orbital fracture (trauma) proved by ct scan and need operative repair. * agree to participate. exclusion criteria: * patients that refuse to be included in the study. * under the age of 18 years. * ct not performed or not available. * not qualified to sign the consent form.

Keywords: orbit fracture measurement ct intraoperative